Your session is about to expire
← Back to Search
Inclisiran for Acute Coronary Syndrome (V-INCEPTION Trial)
V-INCEPTION Trial Summary
This trial will study whether inclisiran, a new cholesterol-lowering drug, is effective in reducing LDL-cholesterol in patients who have recently experienced an ACS and are already taking a statin drug.
V-INCEPTION Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowV-INCEPTION Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 482 Patients • NCT03397121V-INCEPTION Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have high LDL-C or non-HDL-C levels.My kidney function, measured by eGFR, is above 20 mL/min.I have a serious illness besides heart disease that may shorten my life to under 2 years.I have had or will have a heart vessel procedure within 2 weeks around my study entry.I have had serious heart rhythm problems in the last 3 months that are not controlled by medication or procedures.I am on statin therapy or cannot take statins due to severe side effects.I haven't used any experimental drugs or devices in the last 30 days or longer.My heart's pumping ability is severely reduced.My kidney function, measured by eGFR, is above 20 mL/min.I had a heart attack or severe chest pain within the last 5 weeks.I have not taken PCSK9 inhibitors in the last 90 days.I had a heart problem again less than 2 weeks ago.I am on statin therapy or cannot take it due to severe side effects.I had a heart attack or related issue within the last 5 weeks.You cannot use any experimental products or devices during the study.
- Group 1: Inclisiran with Usual Care
- Group 2: Usual Care
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
For what purpose is Inclisiran primarily being prescribed?
"Inclisiran is commonly used to treat primary hypercholesterolemia. However, it can also be employed to help manage diet and atherosclerotic cardiovascular diseases."
What are some other instances where Inclisiran has been studied?
"The first clinical trials for inclisiran occurred in 2018 at the TIMI Study Group. Presently, there are 11 completed studies and 11 active ones. Out of all the locations where these studies take place, a significant number occur in Pittsburgh, Pennsylvania."
How does Inclisiran's safety profile compare to other drugs?
"Inclisiran has received a score of 3 for safety from our team at Power. This is because there is some efficacy data as well as multiple rounds of supportive safety data, meaning that it is a Phase 3 trial."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger